BC Extra | Jun 24, 2019
Company News

Management Tracks: Kress to succeed Moroney at MorphoSys; plus Sutro, Entasis and more

MorphoSys AG (Xetra:MOR; NASDAQ:MOR) said Jean-Paul Kress will take over as CEO from Simon Moroney, who in February announced his decision not to renew his contract as a member of MorphoSys’ management board, on Sept....
BC Extra | Jun 11, 2019
Company News

Ahead of Phase III data, Zai adds Deciphera's GIST candidate to gastric cancer franchise

With a Phase III readout imminent for Deciphera's kinase switch control inhibitor ripretinib in GIST, Zai Lab has obtained the compound's rights in Greater China, adding to a planned gastric cancer franchise it has built...
BC Extra | May 24, 2019
Company News

May 24 Company Quick Takes: End of Alpine-Kite deal; plus Jakafi label expansion and more

Kite ends immunotherapy deal with Alpine  Alpine Immune Sciences Inc. (NASDAQ:ALPN) said Kite Pharma Inc. terminated a 2015 deal to discover and develop protein-based immunotherapies targeting the immune synapse to treat cancer. The deal granted...
BC Extra | May 3, 2019
Financial News

With potential launches nearing, Zai taps investors for $200M

Eight months after raising $150 million in a follow-on, Zai has returned to the well to raise $200 million in an upsized offering as it prepares for a pair of potential launches in mainland China....
BC Innovations | Mar 29, 2019
Targets & Mechanisms

AACR moves in a myeloid direction

Myeloid cells are showing up everywhere at this year’s AACR conference, suggesting the research community is rapidly expanding the ways it can harness the cell types to improve cancer immunotherapy responses. One of those ways...
BC Extra | Mar 22, 2019
Company News

Management tracks: Mirum, Novocure

Mirum said Mike Grey has stepped down as CEO but will remain executive chairman. Mirum Pharmaceuticals Inc. (San Francisco, Calif.) promoted President Chris Peetz to CEO. Peetz is also a director. Mirum launched in 2018...
BioCentury | Jan 12, 2019
Finance

JPM jump-starts 2019

About three quarters of the more than 200 biopharma companies presenting at the 2019 J.P. Morgan Healthcare Conference saw their stock prices rise last week. Leading the pack was the 53% jump by Insmed Inc....
BC Week In Review | Jan 4, 2019
Company News

Zai launches Optune in Hong Kong for GBM

Zai Lab Ltd. (NASDAQ:ZLAB) said on Dec. 28 it launched glioblastoma multiforme treatment Optune in Hong Kong, a territory it regards as strategic as it plans to seek the therapy’s approval in mainland China. Optune...
BC Extra | Dec 28, 2018
Company News

Zai launches Optune in Hong Kong for GBM

Zai Lab Ltd. (NASDAQ:ZLAB) said Friday it launched glioblastoma multiforme treatment Optune in Hong Kong, a territory it regards as strategic as it plans to seek the therapy’s approval in mainland China. Optune uses Tumor...
BC Extra | Nov 29, 2018
Company News

Zai gains China rights to three MacroGenics immuno-oncology compounds

Zai Lab Ltd. (NASDAQ:ZLAB) bulked up its cancer pipeline Thursday by in-licensing Chinese rights to three immuno-oncology compounds from MacroGenics Inc. (NASDAQ:MGNX), including margetuximab, an Fc optimized mAb against HER2 in Phase III testing for...
Items per page:
1 - 10 of 72
BC Extra | Jun 24, 2019
Company News

Management Tracks: Kress to succeed Moroney at MorphoSys; plus Sutro, Entasis and more

MorphoSys AG (Xetra:MOR; NASDAQ:MOR) said Jean-Paul Kress will take over as CEO from Simon Moroney, who in February announced his decision not to renew his contract as a member of MorphoSys’ management board, on Sept....
BC Extra | Jun 11, 2019
Company News

Ahead of Phase III data, Zai adds Deciphera's GIST candidate to gastric cancer franchise

With a Phase III readout imminent for Deciphera's kinase switch control inhibitor ripretinib in GIST, Zai Lab has obtained the compound's rights in Greater China, adding to a planned gastric cancer franchise it has built...
BC Extra | May 24, 2019
Company News

May 24 Company Quick Takes: End of Alpine-Kite deal; plus Jakafi label expansion and more

Kite ends immunotherapy deal with Alpine  Alpine Immune Sciences Inc. (NASDAQ:ALPN) said Kite Pharma Inc. terminated a 2015 deal to discover and develop protein-based immunotherapies targeting the immune synapse to treat cancer. The deal granted...
BC Extra | May 3, 2019
Financial News

With potential launches nearing, Zai taps investors for $200M

Eight months after raising $150 million in a follow-on, Zai has returned to the well to raise $200 million in an upsized offering as it prepares for a pair of potential launches in mainland China....
BC Innovations | Mar 29, 2019
Targets & Mechanisms

AACR moves in a myeloid direction

Myeloid cells are showing up everywhere at this year’s AACR conference, suggesting the research community is rapidly expanding the ways it can harness the cell types to improve cancer immunotherapy responses. One of those ways...
BC Extra | Mar 22, 2019
Company News

Management tracks: Mirum, Novocure

Mirum said Mike Grey has stepped down as CEO but will remain executive chairman. Mirum Pharmaceuticals Inc. (San Francisco, Calif.) promoted President Chris Peetz to CEO. Peetz is also a director. Mirum launched in 2018...
BioCentury | Jan 12, 2019
Finance

JPM jump-starts 2019

About three quarters of the more than 200 biopharma companies presenting at the 2019 J.P. Morgan Healthcare Conference saw their stock prices rise last week. Leading the pack was the 53% jump by Insmed Inc....
BC Week In Review | Jan 4, 2019
Company News

Zai launches Optune in Hong Kong for GBM

Zai Lab Ltd. (NASDAQ:ZLAB) said on Dec. 28 it launched glioblastoma multiforme treatment Optune in Hong Kong, a territory it regards as strategic as it plans to seek the therapy’s approval in mainland China. Optune...
BC Extra | Dec 28, 2018
Company News

Zai launches Optune in Hong Kong for GBM

Zai Lab Ltd. (NASDAQ:ZLAB) said Friday it launched glioblastoma multiforme treatment Optune in Hong Kong, a territory it regards as strategic as it plans to seek the therapy’s approval in mainland China. Optune uses Tumor...
BC Extra | Nov 29, 2018
Company News

Zai gains China rights to three MacroGenics immuno-oncology compounds

Zai Lab Ltd. (NASDAQ:ZLAB) bulked up its cancer pipeline Thursday by in-licensing Chinese rights to three immuno-oncology compounds from MacroGenics Inc. (NASDAQ:MGNX), including margetuximab, an Fc optimized mAb against HER2 in Phase III testing for...
Items per page:
1 - 10 of 72